Cilofexor

Unassigned

New Medicines

Primary sclerosing cholangitis

Information

New molecular entity
Gilead Sciences
Gilead Sciences

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Non-steroidal agonist of the Farnesoid X receptor (FXR); FXR is the primary regulator of bile acid synthesis and plays important roles in glucose and lipid metabolism
PSC is a rare disease with a prevalence of 0.2-16 per 100,000. PSC commonly affects males with a median age at diagnosis of 35 years. PSC accounts for 10% of all UK liver transplants [1].
Primary sclerosing cholangitis
Oral